FGFR2 and cholangiocarcinoma: Among cholangiocarcinoma patients with FGFR fusions or rearrangements, 35.5% achieved an objective response when treated with second-line pemigatinib, an oral inhibitor of FGFR1, FGFR2, and FGFR3 [34].